Europe Botulinum Toxin Market Forecast to 2031

At 12.1% CAGR, Europe Botulinum Toxin Market is Speculated to be Worth US$ 2,931.74 Million by 2031, says The Research Team

According to The Research Team’ research, the Europe botulinum toxin market was valued at US$ 1,174.94 million in 2023 and is expected to reach US$ 2,931.74 million by 2031, registering a CAGR of 12.1% from 2023 to 2031. Rising popularity of noninvasive aesthetics procedures and increasing use of botulinum toxin for enhancing facial aesthetics are among the critical factors attributed to drive the Europe botulinum toxin market growth.

Cosmetic surgery and injectable botulinum toxin are among the most popular noninvasive rejuvenation procedures. According to the ISAPS, in 2020, the botulinum toxin treatment was the leading noninvasive cosmetic procedure performed worldwide. Moreover, the use of botulinum toxin type A-based (BoNTA) cosmetic facial treatments are performed to improve the aesthetics of the upper and lower face. In the last decade, a facial rejuvenation procedure has gained significant popularity over different types of traditional surgeries. According to the ISAPS, ~7.3 million botulinum toxin procedures were performed globally in 2020. Thus, the surge in the adoption of botulinum toxin in facial aesthetic procedures for both men and women from all age groups is driving the botulinum toxin market growth.

On the contrary, side effects of botulinum toxin hamper the growth of Europe botulinum toxin market.

Based on product, the Europe botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held 94.5% share of Europe botulinum toxin market share in 2023, amassing US$ 1,109.89 million. It is projected to garner US$ 2,809.10 million by 2031 to register 12.3% CAGR during 2023–2031.

In terms of application, the Europe botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held 58.2% share of Europe botulinum toxin market in 2023, amassing US$ 684.15 million. It is anticipated to garner US$ 1,797.62 million by 2031 to expand at 12.8% CAGR during 2023–2031. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.

By end user, the Europe botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held 51.6% share of Europe botulinum toxin market in 2023, amassing US$ 606.83 million. It is projected to garner US$ 1,599.26 million by 2031 to expand at 12.9% CAGR from 2023 to 2031.

Based on country, the Europe botulinum toxin market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 31.2% share of Europe botulinum toxin market in 2023. It was assessed at US$ 364.94 million in 2023 and is likely to hit US$ 943.10 million by 2031, registering a CAGR of 12.6% during 2023–2031.

Key players operating in the Europe botulinum toxin market are Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, and Galderma SA, among others.

In August-2021, Merz Therapeutics has been granted the use of XEOMIN for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level. The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration approved in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021. XEOMIN is first and only botulinum neurotoxin approved for this indication in Europe.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe botulinum toxin market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Europe botulinum toxin market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe botulinum toxin market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Botulinum Toxin Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
4.3.1 Aging Population
4.4 Future Trends
4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:
5. Botulinum Toxin Market – Europe Analysis
5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021–2031
6. Europe Botulinum Toxin Market Analysis – by Product
6.1 Overview
6.2 Botulinum Toxin A
6.2.1 Overview
6.2.2 Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
6.3.1 Overview
6.3.2 Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7. Europe Botulinum Toxin Market Analysis – by Application
7.1 Overview
7.2 Medical
7.2.1 Overview
7.2.2 Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.2.2.1 Europe Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
7.3.1 Overview
7.3.2 Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 Europe Botulinum Toxin Market Breakdown, by Aesthetic
8. Europe Botulinum Toxin Market Analysis – by End User
8.1 Overview
8.2 Specialty and Dermatology Clinics
8.2.1 Overview
8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
8.3.1 Overview
8.3.2 Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9. Europe Botulinum Toxin Market – Country Analysis
9.1 Europe: Botulinum Toxin Market
9.1.1 Europe: Botulinum Toxin Market – Revenue and Forecast Analysis – by Country
9.1.1.1 Germany
9.1.1.1.1 Overview
9.1.1.1.2 Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.1.3 Germany: Botulinum Toxin Market Breakdown, by Product
9.1.1.1.4 Germany: Botulinum Toxin Market Breakdown, by Application
9.1.1.1.4.1 Germany: Botulinum Toxin Market Breakdown, by Medical
9.1.1.1.4.2 Germany: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.1.5 Germany: Botulinum Toxin Market Breakdown, by End User
9.1.1.2 United Kingdom
9.1.1.2.1 Overview
9.1.1.2.2 United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.2.3 United Kingdom: Botulinum Toxin Market Breakdown, by Product
9.1.1.2.4 United Kingdom: Botulinum Toxin Market Breakdown, by Application
9.1.1.2.4.1 United Kingdom: Botulinum Toxin Market Breakdown, by Medical
9.1.1.2.4.2 United Kingdom: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.2.5 United Kingdom: Botulinum Toxin Market Breakdown, by End User
9.1.1.3 France
9.1.1.3.1 Overview
9.1.1.3.2 France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.3.3 France: Botulinum Toxin Market Breakdown, by Product
9.1.1.3.4 France: Botulinum Toxin Market Breakdown, by Application
9.1.1.3.4.1 France: Botulinum Toxin Market Breakdown, by Medical
9.1.1.3.4.2 France: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.3.5 France: Botulinum Toxin Market Breakdown, by End User
9.1.1.4 Italy
9.1.1.4.1 Overview
9.1.1.4.2 Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.4.3 Italy: Botulinum Toxin Market Breakdown, by Product
9.1.1.4.4 Italy: Botulinum Toxin Market Breakdown, by Application
9.1.1.4.4.1 Italy: Botulinum Toxin Market Breakdown, by Medical
9.1.1.4.4.2 Italy: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.4.5 Italy: Botulinum Toxin Market Breakdown, by End User
9.1.1.5 Spain
9.1.1.5.1 Overview
9.1.1.5.2 Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.5.3 Spain: Botulinum Toxin Market Breakdown, by Product
9.1.1.5.4 Spain: Botulinum Toxin Market Breakdown, by Application
9.1.1.5.4.1 Spain: Botulinum Toxin Market Breakdown, by Medical
9.1.1.5.4.2 Spain: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.5.5 Spain: Botulinum Toxin Market Breakdown, by End User
9.1.1.6 Rest of Europe
9.1.1.6.1 Overview
9.1.1.6.2 Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.6.3 Rest of Europe: Botulinum Toxin Market Breakdown, by Product
9.1.1.6.4 Rest of Europe: Botulinum Toxin Market Breakdown, by Application
9.1.1.6.4.1 Rest of Europe: Botulinum Toxin Market Breakdown, by Medical
9.1.1.6.4.2 Rest of Europe: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.6.5 Rest of Europe: Botulinum Toxin Market Breakdown, by End User
10. Company Profiles
10.1 Merz Pharma GmbH & Co KGaA
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 AbbVie Inc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Ipsen SA
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Evolus Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Medytox Inc
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Galderma SA
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
11. Appendix
11.1 About The Research Team

LIST OF TABLES

Table 1. Botulinum Toxin Market Segmentation
Table 2. Europe Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 3. Europe Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 4. Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 5. Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 6. Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 7. Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 8. Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 9. United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 10. United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 11. United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 12. United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 13. United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 14. France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 15. France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 16. France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 17. France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 18. France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 19. Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 20. Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 21. Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 22. Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 23. Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 24. Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 25. Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 26. Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 27. Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 28. Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 29. Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 30. Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 31. Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 32. Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 33. Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 34. Glossary of Terms

LIST OF FIGURES

Figure 1. Botulinum Toxin Market Segmentation, by Country
Figure 2. Botulinum Toxin Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021–2031
Figure 5. Botulinum Toxin Market Share (%) – by Product (2023 and 2031)
Figure 6. Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Botulinum Toxin Market Share (%) – by Application (2023 and 2031)
Figure 9. Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Botulinum Toxin Market Share (%) – by End User (2023 and 2031)
Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Europe: Botulinum Toxin Market, by Key Country – Revenue (2023) (US$ Million)
Figure 16. Europe: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 17. Germany: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. United Kingdom: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. France: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Italy: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Spain: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Rest of Europe: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)